Inovalon — Q4 2019 Earnings Presentation
34 slides from Inovalon's earnings presentation, Feb 19, 2020
Slide 1: Q4 & Full Year 2019 Earnings Supplement
Q4 & Full Year 2019 Earnings Supplement February 19, 2020
Slide 2: Cautionary Note Regarding Forward-Looking Statement
Cautionary Note Regarding Forward-Looking Statement Certain statements contained in this presentation constitute forward-looking statements within the meaning of, and are intended to be covered by the safe harbor provisions of, Section 27A of the Securities Act of 1933, as amended, and Section 21E o
Slide 3: Contents
Contents 1 Overview 2 2019 Q4 & FY Financial Results This presentation serves as a supplement to the Inovalon announcement on February 19, 2020 pertaining to fourth quarter (Q4) and full 3 2020 Financial Guidance year 2019 results and 2020 guidance. 4 Appendix 1: Reconciliations INOV Q4 & FY 2019 Ea
Slide 4: The Inovalon ONE Platform
Payers Pharmacies Pharmaceuticals Devices Diagnostics The Inovalon ONE® Platform Inovalon is a leading provider of cloud- based platforms empowering data-driven healthcare. Inovalon provides cloud-based, real-time Massive Advanced Intervention Data connectivity, analytics, intervention, and Data Ass
Slide 5: Empowering Data-Driven Healthcare In Scale
Empowering Data-Driven Healthcare In Scale The reach of Inovalon’s platform has grown to touch the vast majority of the United States, able to empower the market’s largest data-driven healthcare initiatives. 100s Health Plans, Providers, Life Sciences, Pharmacy, and Diagnostics Organizations 314M+ P
Slide 6: Executing on Strategy
Executing on Strategy During 2019, Inovalon continued to execute on its three guideposts of its strategy. Inovalon Lead in Innovation Become the Enablement Layer Land and Expand Efficiently Bring to market the industry’s most Leverage the resulting capabilities of the Provide capabilities in highly
Slide 7: Cloud-Based Platform Approach
Cloud-Based Platform Approach Inovalon provides its solutions to the marketplace through the Inovalon ONE® Platform: an integrated, real-time cloud native platform which brings together the capabilities of extensive healthcare ecosystem connectivity, massive scale datasets, advanced analytics, and d
Slide 8: Massive Data Assets
Massive Data 54 MORE2 REGISTRY® DATASET GROWTH Assets 52 50 Patient Count Medical Event Count 48 Inovalon leverages massive datasets to 46 deliver differentiated capabilities to its clients. 44 42 These datasets are expanding rapidly. As of the 40 end of Q4 2019, the MORE2 Registry® dataset 38 36 59
Slide 9: Benefits of Inovalon's Massive Primary-Source Dataset
Benefits of Inovalon’s Massive Primary-Source Dataset The significant size, extensive breadth of data types, historical duration, recency timeliness, and fully linkable primary-sourced nature of Inovalon’s datasets provides a uniquely rich, longitudinally matched real-world dataset able to empower h
Slide 10: Highly Differentiated Within the Market
Highly Differentiated Within the Market A leader in providing cloud-based tools to support data-driven healthcare, Inovalon empowers clients to achieve their clinical quality and financial goals by bringing highly differentiated capabilities to bear – unavailable from any other platform provider. Ma
Slide 11: Cloud-Based Healthcare Data Lake Offering
Cloud-Based Healthcare Data Lake Offering On January 13, 2020, Inovalon announced the newest addition to its cloud-based solution offerings, a cloud-based healthcare data lake, with a five-year contract with a leading healthcare organization executed during Q4 2019. The cloud-based Healthcare Data L
Slide 12: Contents
Contents 1 Overview 2 2019 Q4 & FY Financial Results This presentation serves as a supplement to the Inovalon announcement on February 19, 2020 pertaining to fourth quarter (Q4) and full 3 2020 Financial Guidance year 2019 results and 2020 guidance. 4 Appendix 1: Reconciliations INOV Q4 & FY 2019 Ea
Slide 13: Record Q4 2019 Financial Highlights
Record Q4 2019 60% Quarterly Revenue YoY Growth in of Financial New Sales Annual $173.5M Contract Value (ACV) Representing Highlights to a Record Organic Revenue Growth of Inovalon’s Q4 2019 execution and financial performance was strong. Inovalon signed $73.5M 27% new and expanded contracts, result
Slide 14: Adjacent Market Expansion & Diversification
Adjacent Market Expansion & Diversification Demand for Inovalon’s cloud-based platforms and data-driven capabilities is driving expansion not only in the Company’s original area of focus, the payer landscape, but also in the pharmacy/life sciences and provider landscapes, resulting in greater divers
Slide 15: Continued Strong Sales Performance
Continued Strong Sales Performance The combination of strong demand for the Company’s cloud-based platform capabilities and significant increases in the Company’s sophistication and scale of sales capabilities is resulting in significant contract signings. Q4 2019 total new sales Annual Contract Val
Slide 16: Continued Strong Growth
Continued Strong Growth The strong market demand for Inovalon’s cloud-based platforms and data-empowered capabilities, together with the growing sophistication of sales and the increasing operating leverage of the Company’s technologies and business model, is driving both meaningful momentum and str
Slide 17: Continued Salesforce Expansion
Continued Salesforce Expansion Through 2019, Inovalon continued to significantly increase the scale and sophistication of its salesforce. Furthermore, unlike previously when the Company would lead with healthcare subject matter expertise with support from technology personnel, the Company now leads
Slide 18: Increasing Headcount Efficiency
Increasing Headcount Efficiency The Company’s transition to higher-valued cloud-based offerings leveraging increased connectivity, software automation, SaaS- based, and subscription-based offerings has witnessed a substantial corresponding decrease in headcount while concurrently expanding revenue a
Slide 19: Contents
Contents 1 Overview 2 2019 Q4 & FY Financial Results This presentation serves as a supplement to the Inovalon announcement on February 19, 2020 pertaining to fourth quarter (Q4) and full 3 2020 Financial Guidance year 2019 results and 2020 guidance. 4 Appendix 1: Reconciliations INOV Q4 & FY 2019 Ea
Slide 20: Strong Subscription-Based Platform Adoption
Strong Subscription-Based Platform Adoption The graphic below illustrates the revenue offering mix, which includes the Company’s reaffirmed 2020 guidance range as of February 19, 2020. $698 - $718 $642.4 ~10% 2016 – 2020G 11% ~6% Subscription-Based CAGR 27% $527.7 6% 11% $449.4 $427.6 9% 12% 15% 19%
Slide 21: Revenue
Revenue The following 2020 revenue guidance is being reaffirmed as of February 19, 2020. $698 - $718 $642 2016 – 2020G 13% CAGR $528 $449 $428 2016 2017 2018 2019 2020G Note: CAGR calculations undertaken to the mid-point of 2020 Guidance. All numbers in millions. Graphic drawn at midpoint of guidanc
Slide 22: Expected Quarterly Revenue Cadence
Expected Quarterly Revenue Cadence The following illustration outlines the Company’s expected 2020 quarterly revenue cadence, which reflects 9% to 12% year-over-year organic revenue growth. 9% to 12% YoY Organic Quarterly Revenue Growth Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2019 2019 2019 2020 2020 2020 2020
Slide 23: Adjusted EBITDA
Adjusted EBITDA The following 2020 Adjusted EBITDA guidance is being reaffirmed as of February 19, 2020. $231 - $241 $211 2016 – 2020G 24% CAGR $152 $109 $100 33% 33% 29% 23% 24% 2016 2017 2018 2019 2020G % of Revenue Note: CAGR calculations undertaken to the mid-point of 2020 Guidance. All numbers
Slide 24: Cash Flow From Operations
Cash Flow From Operations The following 2020 Cash Flow from Operations guidance is being reaffirmed as of February 19, 2020. 2 $170 - $185 2016 – 2020G 18% CAGR $106 $1041 $98 $93 $90 25% 22% 22% 17% 17% 2016 2017 2018 2019 2020G % of Revenue Note: CAGR calculations undertaken to the mid-point of 20
Slide 25: CAPEX Returning Towards Historical Levels
CAPEX Returning Towards Historical Levels During the period Q3 2016 through Q1 2018, the Company elected to invest more than $40M into incremental development towards the launch of the Inovalon ONE® Platform. The period of this disproportional investment is now complete and is increasingly being har
Slide 26: Covenant-Lite Debt Leverage
Covenant-Lite Debt Leverage On April 2, 2018, the Company put in place a $980M seven-year term debt facility and $100M five-year revolving debt facility. Proceeds were used, among other things, to pay off all of the Company’s existing debt obligations of $225M as well as to provide the financing nec
Slide 27: Full Year 2020 Financial Guidance
Full Year 2020 Financial Guidance The Company is updating its full-year 2020 guidance to raise its expected net income range, raise its diluted net income per share range, raise its non-GAAP net income range, raise its non-GAAP diluted net income per share range, and net cash provided by operating a
Slide 28: Q1 2020 Financial Guidance
Q1 2020 Financial Guidance Inovalon is providing Q1 2020 guidance as provided below, indicating 9% to 12% year-over-year organic revenue growth. Q1 2019 Financial YoY Financial Metric Guidance Change Revenue $158.5 million to $163 million 9% to 12% Net Income 1 $0 million to $2 million --- Non-GAAP
Slide 29: Contents
Contents 1 Overview 2 2019 Q4 & FY Financial Results This presentation serves as a supplement to the Inovalon announcement on February 19, 2020 pertaining to fourth quarter (Q4) and full 3 2020 Financial Guidance year 2019 results and 2020 guidance. 4 Appendix 1: Reconciliations INOV Q4 & FY 2019 Ea
Slide 30: Reconciliation of Forward-Looking Guidance Adjusted EBITDA
Reconciliation of Forward-Looking Guidance Adjusted EBITDA Inovalon defines Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) as net income or loss calculated in accordance with GAAP, adjusted for the impact of depreciation and amortization, other expense, net
Slide 31: Reconciliation of Forward-Looking Guidance Non-GAAP Net Income
Reconciliation of Forward-Looking Guidance Non-GAAP Net Income Inovalon defines Non-GAAP net income as net income or loss calculated in accordance with GAAP, adjusted to exclude tax-affected stock-based compensation expense, acquisition costs, restructuring expense, amortization of acquired intangib
Slide 32: Definitions
Definitions 1. Annual Recurring Revenue is defined as subscription-based revenue from existing clients plus outstanding intra-year renewals valued at an amount agreed upon in principal. 2. Annual Revenue Retention is defined as the percentage of revenue from engagements with existing clients in the
Slide 33: ACV, TCV and Bookings
ACV, TCV and Bookings Inovalon’s sales have significantly expanded and accelerated, supporting strong growth going forward. The Company started reporting its sales performance in 2018 by providing new sales Annual Contract Value (ACV) data, a metric reflecting the sum of the first 12 months of reven
Slide 34: Healthcare Empowered
Healthcare Empowered® © 2020 by Inovalon. All rights reserved.